Introduction
============

Pancreatic cancer (PC) is one of the neoplasias with worse prognosis and despite the increased efforts in research, progress in patient\'s survival has remained slow with a 5-year survival rate estimated in 2016 of 8%[@B1]. It is expected that PC death rate will increase being the second leading cause of cancer-related death by 2030[@B2].

Since pancreatic ductal adenocarcinoma (PDAC) is the predominant pancreatic tumor type, we will refer to this pathology as PC.

Majority of PC cases (\>80%) are considered *sporadic*, due to sporadic mutations. The main modifiable risk factors are smoking, obesity, diabetes mellitus, non-O blood group, *Helicobacter pylori* infection and chronic pancreatitis. While all of these factors increase risk up to 2 fold, chronic pancreatitis could give up to 13.3 fold of higher risk[@B3].

*Hereditary pancreatic cancer* (accounts for 5-10% of cases) is defined as a genetic syndrome with an identifiable gene mutation associated with an increased risk for PC. These mutations are principally BRCA2, p16, ATM, STK11, PRSS1/PRSS2, SPINKI, PALB2 and DNA mismatch repair genes (MMR)- each one associated to increased risk for PC development[@B4]. However, BRCA2 is probably the most common inherited disorder.

Considering pathologies, individuals should be considered to be at risk for PC if they have hereditary pancreatitis, cystic fibrosis or other PC-related syndromes. These other syndromes linked to PC risk include Lynch syndrome (LS), Peutz-Jeghers syndrome (PJS), Familial atypical multiple mole melanoma syndrome (FAMMM) and Li-Fraumeni syndrome.

*Familial Pancreatic Cancer (FPC)* is defined as a family with at least one pair of first-degree relatives (parent-child or sibling pair) with PC without an identifiable syndrome in the family[@B5].

Lynch Syndrome Definition and Types
===================================

LS, formerly known as hereditary nonpolyposis colorectal cancer or HNPCC was firstly described by Warthin in 1913 and it is an autosomal dominant disease caused by germline mutation in MMR genes MLH1, MSH2, MSH6 and PMS2, or by germline mutation in EPCAM which causes epigenetic silencing of MSH2 [@B6], [@B7].

LS is suspected on the basis of patient and family history, MMR protein expression pattern and Microsatellite instability (MSI) phenotype. The incidence of this syndrome has been postulated to be between 1:660 and 1:2000[@B8].

MMR mutation is generally inherited from one parent and patient has every cell in the body with one defective copy of the particular gene and a fully functional copy that maintains DNA repair in cells. A cell develops a DNA repair defect only when this functional copy of the gene becomes nonfunctional as a result of a random somatic mutation[@B9].

There are two forms of LS: Type I, the one limited to colon specific syndrome and type II, that includes cancer in different anatomic sites such as endometry, ovary, pancreas, etc.

As determined in the *ACG Clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes*, LS should be considered in individuals whose tumors show evidence of MMR deficiency (without the presence of a *BRAF* mutation or MLH1 promoter hypermethylation), and those whose personal and/or family history fullfill the Amsterdam criteria, Bethesda Guidelines (Available from <http://www.nccn.org/professionals/physician_gls/f_guidelines.asp>) or who have a ≥5% risk of carrying a germline mutation based on available prediction models[@B10], [@B11].

The primary strategy currently used in routine practice to identify LS patients is tumor sample evaluation for evidence of high level MSI (MSI-H) and/or DNA MMR deficiency (MMR-D)[@B10], [@B11]. Several studies have consistently demonstrated that universal tumor testing- mostly by using Polymerase chain reaction (PCR) for MSI testing and immunohistochemical staining for MMR protein expression of all CRC tumors is a more effective way to screen LS compared to previous guidelines based on Bethesda guidelines or Amsterdam criteria. However, successful results depend on availability of both, healthy and cancer relatives undergoing genetic testing[@B12], [@B13].

LS accounts for approximately 2-5% of all colorectal cancers (CRC) diagnosis and is the most common cause of inherited colon cancer conferring a lifetime risk between 52-82% with a mean diagnosis age of 44 years. However, endometrial tumors occur with a similar frequency to colon cancer in woman with LS. LS also confers an increased risk of other types of tumors such as endometrial (lifetime risk 25-60%), ovarian (4-12%), gastric (6-13%), pancreatic (1.3-4%), ciliary tract and kidney cancer[@B14]-[@B17]. This means that LS patients frequently develop colorectal cancer before the age of 50 and approximately one-third of them develop another LS typical tumor within 10 years[@B18].

In this review, we will focus on PC- cases reported, increased risk and current management guidelines.

Genetic association of LS and PC
================================

LS is an autosomal dominant hereditary disorder due to mutation in a mismatch repair (MMR) genes. In PC cases derived from LS, mutations have been specifically described in genes encoding DNA reparation proteins: MLH1 (mutL homolog 1), MSH2, MSH6 (mutS homolog 2 y 6, respectively), PMS2 (PMS1 homolog 2, mismatch repair system component). Less frequently, PALB2 (partner and localizer of BRCA2) and EPCAM (Epithelial cell adhesion molecule) gene located upstream of MSH2 have been seen in LS patients diagnosed with PC. EPCAM deletions lead to a transcriptional read-through, hypermethylation and subsequent silencing MSH2 and are estimated to cause Lynch syndrome in \~20-25% of patients with MSH2-negative cancers, but no detectable MSH2 germline mutation[@B6].

Mutations in the MLH1 and MSH2 genes have more effect on DNA repair than mutations in MSH6 or PALB2. Patients with an MLH1 or MSH2 mutation therefore have a substantially higher risk of tumors than patients with an MSH6 mutation. The risk of patients with a PMS2 mutation seems to be even lower than that of patients with an MSH6 mutation[@B9].

As it occurs in other type of LS tumors, defect in the DNA mismatch repair system increase the error rate of replication by 100 to 1000 fold. Areas of the genome that contain repetitive sequences (microsatellites) are particularly susceptible to insertion and deletion of bases during the replication process. Errors produces in the DNA sequence are recognized by proteins such as MSH2 or MHS6 [@B19].

Typically these alterations are germline mutations and genetic testing of patients should include germline mutation genetic testing for the *MLH1*, *MSH2*, *MSH6*, *PMS2*, and/or *EPCAM* genes or the altered gene(s) indicated by immunochemistry testing[@B11].

MSI-H tumors have been associated with poor differentiation and the presence of wild type KRAS and p53 genes (frequently mutated in sporadic cases os PC). Moreover, patients with MSI-H tumors have longer overall survival compared to those with MSI-L or MSS tumors[@B20]. Additionally, some authors support that MSI and MMR loss of expression in LS is associated to medullary carcinomas of pancreas[@B17], [@B21].

Next generation data could help to identify other mutations and epigenetic modifications occurring in tumor suppressor genes and oncogenes finally responsible for neoplastic transformation. Confirmatory statements about mutational status in genes frequently alternated in PC such as KRAS, SMAD4, TP53, CDKN2A are still needed.

Reported cases of PC in the literature
======================================

The accumulated risk of PC in LS patients is around 3.7%[@B22] (it is 1.5% in general population)[@B17], [@B23], [@B24]. It has been described that pancreatic tumors developed by LS patients often have a characteristically medullary appearance[@B21], [@B25], with prominent lymphocytic infiltration and MSI[@B26].

When a search for \'\'Lynch syndrome & pancreatic cancer\'\' was performed, as shown in Figure [1](#F1){ref-type="fig"}, 106 records were identified from PubMed database. If research was done for terms \'\'hereditary nonpolyposis colorectal cancer & pancreatic cancer\'\' 79 records were found; however, all of them except one (non-specific) were duplicated of those included in the 106.

Considering the 106 cases after removing 71 \'\'related but not specific or irrelevant\'\' records, we found 17 review/guidelines, 3 IPMN-related cases and 15 relevant descriptive cases. Here, we present summary of the total 18 reporting PC cases in LS patients. A note with these studies is presented in Table [1](#T1){ref-type="table"}.

Lynch *et al.* were the first in 1985 reporting an increased risk of developing PC in LS families[@B27]. They described a kindred with vertical transmission of cancer through 5 generations in which HNPCC and PC was shared.

Since 1985, several authors have described cases and incidence of PC around the world. Wei *et al.*[@B28] in 2002 reviewed 10 Taiwanese families including a total of 202 individuals meeting Amsterdam criteria for LS and they found one PC case. Geary *et al.* in 2008 examined 982 cancers in 723 individuals who belonged to 130 families and found 22 PC, 14 of them diagnosed before the age of 60[@B29]. In this series, PC was the third more frequent after colorectal and endometrial cancer. In 2009, Gargiulo et al.[@B30] noted that estimated frequency of LS was small since among 135 PC patients they only found 19 LS carriers. Kastrinos *et al.* analyzed 6342 individuals from 147 families with MMR gene mutations. Thirty-one families (21.1%) reported at least 1 PC case. Forty-seven pancreatic cancers were reported (21 men and 26 women), with no sex-related difference in age of diagnosis (51.5 *vs* 56.5 years for men and women, respectively). The cumulative risk of PC in these families with gene mutations was 1.31% up to age 50 years and 3.68% up to age of 70 years, which represents an 8.6-fold increase compared with the general population[@B17]. In 2011 Kempers *et al.*[@B31] evaluated 194 carriers of an EPCAM deletion and four were found to have PC and Lindor et al. reported a family in which MSH2 P349L missense alteration cosegregatated with PC in 3 first degree relatives (FDR)[@B32]. Recently, in early 2017 Dymerska *et al.*[@B33] reported the presence of a founder mutation (c.858+2478\_\*4507del) in eight Polish families. Laghi et al. in 2012 evaluated 338 consecutive PDAC in German and Italian centers concluding that MSI prevalence is negligible for sporadic PC. Differently, the prevalence of PC is 2.5% in LS patients[@B34].

In 2015, Salo-Mullen *et al.* published a study in which they analyzed mutations in 159 PC patients identifying 24 pathogenic mutations including BRCA2, BRCA1, p16, PALB2 and LS[@B35]. Four different mutations in MSH2 and MLH1 were found in these LS patients and they were especially frequent in early new onset disease.

Catts *et al.*[@B36] conducted a retrospective review of PC families in US from 2002 to 2013. They analyzed familial pancreatic cancer individuals (including FPC criteria subjects, individuals with only one first-degree relative affected by PC \[first-degree families\] and PC affected). 175 families completed a testing: 46 being FPC and 99 first-degree families. 16 out 46 FPC went LS testing and pathogenic mutations in MMR were identified in 2 of them: one in MLH1 and one in MSH2. 32 out the 99 first-degree families went LS testing and 4 of them had pathogenic mutation: three in MLH1 and one in MSH6. Authors concluded that in FPC, breast and ovarian cancer and then LS are the most prevalent syndromes leading to PC. Cajal *et al.*[@B37] identified a mutation n c.2252_2253delAA, p.Lys751Serfs\*3 en el exón 19 del gen MLH1 in an Italian patient. This mutation was previously noted as pathogenic in Korea, Denmark, United Kingdom, Germany and Australia and described by Borrelli et al.[@B38] in a MLH1 mutation (c2253_2253delAA) that co-segregates with LS cancer in 11 unrelated families. All families had at least one colon cancer diagnosed before age of 50 and one case with multiple LS related tumors. Interestingly, a statistically significant association was found with higher frequency of PC compared to families with other MLH1 mutations.

While all the publications presented above reported an increased rate of pancreatic cancer in LS families and patients, another study published by Barrow *et al.*[@B16] in 2009 observed no excess risk. Additionally, two additional studies in the literature reported in the eighties and nineties found no high correlation between LS and PC since in a study of 40 Finnish LS kindreds, only 6 out of 243 carriers with clinically or histologically cancer had PC[@B39]. Conversely, no PC was found in a series of 22 Dutch LS families with at least one person diagnosed with PC[@B40].

Although LS has been clearly associated with PC (understood as Pancreatic Ductal Adenocarcinoma-PDAC), no clear connection has been established with pancreatic neoplasic precursor lesions in these patients. Only a few recent publications have demonstrated that intraductal papillary mucinous neoplasm (IPMN) could be LS related and consequently, these lesions should be carefully considered at patient\'s screening.

Firstly, in 2009, Sparr *et al.*[@B41] described the case of a 61-year old woman with LS and multiple cancers including colorectal adenocarcinoma and IPMN. More recently, a case of a 58 year-old woman was reported by Flanagan et al. This LS patient (exon 1 deletion in MSH2 that was classified as a suspected deleterious change) was diagnosed firstly with colorectal cancer, then uterine and breast cancer and finally CT images showed a progression of main duct IPMN to invasive pancreatic ductal adenocarcinoma. Due to LS and previous history of cancer, distal pancreatectomy was indicated. However, MMR immunohistochemical stain was negative for MLH1, PMS2, MSH2 and MSH6[@B42]. Finally, Lee *et al.* reported a case of a 49 year-old woman diagnosed with LS, past history of colon and endometrial carcinoma in which IPMN originated from the ideal heterotopic pancreas was surgically resected. It was positive for MLH1/PMS2 and negative for MSH2/MSH6[@B43].

All of this data suggest that IPMN are part of the spectrum of lesions found in LS.

Moreover, Acinar cell carcinoma (ACC)- a rare pancreatic malignancy has been documented by Liu et al.[@B44] in 36 ACC cases, of which 5 were MMR deficient and 2 out of these 5 were LS. ACC was also reported by Karamurzin *et al.*[@B45] in a single case.

Strategies for PC in LS patients
================================

It is well known that screening general population for PC is not cost-effective and screening strategy has been only confined to *High Risk (HR) Population*- defined as subjects with 6-8 times higher risk of having PC compared with age-matched controls. This HR group, as established now, includes individuals with 2 first-degree relatives with PC which is the cohort currently screened for familial PC[@B46]. Additionally, and still controversial is to include new onset diabetes subjects older than 50 years, which as demonstrated by Chari et al.[@B47] have 6-8 fold higher probability of being diagnosed with PC, as HR. This last scenario is nowadays more accepted in US than in Europe or any other country.

For healthy individuals who have a germline mutation in a gene linked to PC risk, as it is the case of LS, the priority is to manage and reduce PC risk due to the importance of early diagnosis in this disease. However, in this case of healthy LS individuals, factual risk and clear strategies are not yet uniform and well-defined.

If, as demonstrated by some authors, patients with LS have an 8.6-fold increased risk of developing PDAC compared to the general population[@B17], they should then considered as HR subjects and consequently, enter clearly into screening programs.

In one side, it has been purposed in 2011 by the International Cancer of the pancreas screening (CAPS) consortium that LS patients and one first-degree relative with PC should be candidates for screening[@B48]. On the other side, it is indicated in the summary of recommendations by Syngal *et al.* about how to manage extracolonic neoplasia screening in LS patients: \'\'Screening beyond population-based recommendations for cancers of the urinary tract, pancreas, prostate, and breast is not recommended unless there is a family history of the specific cancers (conditional recommendation, low quality of evidence)\'\'. In this case (family history demonstrated), it can be considered a magnetic resonance imaging (MRI) and/or endoscopic ultrasound every 1-2 years in MMR mutation carriers with PC in a first [@B48] or second-degree relative[@B11] depending on the recommendation guides (Table [2](#T2){ref-type="table"}).

The frequency and age to begin surveillance are not yet well defined. Most centers utilize endoscopic ultrasound and/or MRI surveillance programs, both of which detect pancreatic lesions better than CT[@B49]. Past screening efforts, mostly using HR- FPC, PJS and FAMMM patients have demonstrated diagnostic yields from 1.1 to 50%, depending on their definition of yield[@B3]. However, since it is well-known that in general terms there is not effective screening test for this malignancy, some authors considerer PC a \'\'rare LS related tumor\'\' and no specific screening measures other than abdominal ultrasound and general physical examination is recommended[@B9].

In general it can be said that literature contains little reliable information on screening for other tumors than colorectal and ovarian/endometrio in LS patients. Prospective data indicated that screening colonoscopies beginning in the early 20s can markedly reduce colorectal cancer incidence and colorectal cancer-related mortality in individuals with LS[@B50]. For women with LS, risk-reducing hysterectomy and salpingo-oophorectomy can drastically reduce the risk of endometrial and ovarian cancers[@B51]. Being PC less frequent than these other tumor types, more investigation to reach consensus is needed. PancPro (<https://www4.utsouthwestern.edu/breasthealth/cagene>) is a clinical prediction model that uses personal and family history data, including prior genetic testing results, to estimate an individual\'s future risk of developing pancreatic cancer.

Discussion and conclusion
=========================

PC is a leading cause of cancer death and very few patients are candidates for the only curative option-the surgery. Screening of HR patients amenable to surgical resection should be a priority.

It must be recognized that based on the literature, Peutz-Jeghers syndrome (132 fold), FAMMM syndrome (47 fold) or hereditary pancreatitis (69 fold) confer a bigger increase in PC risk compared to LS (8.6 fold)[@B3]. This is, although PC is not one of the top cancer types in LS patients (lower incidence than colorectal and endometrial tumors), still these patients are considered in high risk- as they present 8.6-fold increase compared with the general population.

As it has been presented above, most of the studies published in the literature (including patients from USA, Europe and Asia) demonstrate a good association of PC in LS kindreds. This review summarizes the studies that should serve to support evidence of PC risk in LS patients.

Accepting this evidence and the clinical need for PC screening in LS individuals, only a few guidelines describe further management strategies. They recommend screening LS individuals MMR carriers with at least one PC case in a FDR. Unfortunately, adequate screening technique for PC does not currently exist and further research must be done and options for these patients include MRI and EUS. However, optimal interval for screening and the management of PC precursor lesions is still controversial[@B52]. Moreover, there is an urgent need to find new biomarkers that could help to screen HR individuals[@B53], including LS patients. How clinicians should fully address PC screening and management is still unclear as many uncertainties in PC and LS remain.

Recent reviews highlight the increasingly recognized role of genetics in the development of PC and associated syndromes. Given the poor prognosis of PC, the development of next-generation genome sequencing will show additional alterations that combined with more powerful screening and surveillance tools may lead to an improved survival[@B54].
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###### 

Most relevant studies supporting evidence of PC in LS patients.

  Most relevant cases described in the literature   Genetic Evidence                       Associated Disease                 Country                             Number LS patients / Number PC cases   \# Reference
  ------------------------------------------------- -------------------------------------- ---------------------------------- ----------------------------------- -------------------------------------- --------------
  Lynch et al. 1985                                 ns                                     PC                                 USA (Nebraska)                      Family Case Report (3 PC)              27
  Wei et al. 2002                                   ns                                     Taiwan                             202 LS/1 PC                         28                                     
  Banville et al. 2006                              MSH2, MLH1 nonsense mutations          Ireland                            Case Report                         21                                     
  Geary et al. 2008                                 ns                                     United Kingdom                     130 LS/22PC                         29                                     
  Barrow et al. 2009                                ns                                     United Kingdom                     938 LS /2 PC                        16                                     
  Vergara-Fernández et al. 2009                     ns                                     Mexico                             Case Report                         25                                     
  Gargiulo et al. 2009                              ns                                     Italy                              \*135 PC/19 LS                      30                                     
  Kastrinos et al. 2009                             MSH2, MLH1, MSH6 mutations             USA (Massachusets)                 147 LS families/47 PC               17                                     
  Kempers et al. 2011                               EPCAM deletions                        The Netherlands                    194 EPCAM deletion carriers/ 4 PC   31                                     
  Lindor et al. 2011                                MSH2 (P349L) missense alteration       USA (Northern European ancestry)   Family Case Report (3 PC)           32                                     
  Laghi et al. 2012                                 MLH1 deficiency and MLH1 methylation   Italy & Germany                    203 LS/5PC                          34                                     
  Borelli et al. 2014                               MLH1 (c.2252_2253delAA) mutation       Italy                              67 LS/ 5 PC                         38                                     
  Salo-Mullen et al. 2015                           MHS2, MLH1, MSH6 mutations             USA (New York)                     \*159 PC/4 LS                       35                                     
  Catts et al. 2016                                 MSH2, MLH1 mutations                   USA (Delaware)                     16 FPC families / 2 LS              36                                     
  Cajal et al. 2016                                 MLH1 (c.2252_2253delAA) mutation       Italy & Spain                      Case Report                         37                                     
  Sparr et al. 2009                                 MSH2, MSH6 mutations                   IPMN                               USA (Massachusets)                  Case Report                            41
  Flanagan et al. 2015                              MSH2 mutation                          USA (Wasintong)                    Case Report                         42                                     
  Lee et al. 2015                                   MHS2, MSH6 mutation?                   South Korea                        Case Report                         43                                     
  Dymerska et a. 2017                               EPCAM mutation                                                            Poland                              Family Case Report (1 PC)              33

Ns, not specified. PC, Pancreatic Cancer; IPMN, intraductal papillary mucinous neoplasms. \* LS mutations (cases) were evaluated in PC patients.

###### 

Guidelines for PC screening in LS patients.

  Management strategy for PC Screening                                                                           Technique           Guidelines/Author recommending                                  Year
  -------------------------------------------------------------------------------------------------------------- ------------------- --------------------------------------------------------------- ------
  \'\'LS individuals with at least one affected FDR with PC\'\'                                                  MRI/EUS/CT/ERCP\*   CAPS International cancer of pancreas screening/Canto et. al.   2011
  \'\'LS-MMR mutation carriers with PC in a FDR\'\' (conditional recommendation; very low quality of evidence)   MRI/EUS             ACG Clinical Guideline/Syngal et. al                            2015

CT, Computed tomography; ERCP, Endoscopic retrograde cholangiopancreatography; LS, Lynch syndrome; FDR, First degree relative; MSI, Magnetic resonance imaging; PC, Pancreatic cancer; \* Initial screening should include (multiple answers allowed): EUS 83.7%, MRI 73.5%, CT 26.5%, abdominal ultrasound 14.3%, ERCP 2.0%. B2 When previous screening did not detect an abnormality that met criteria for shortening of the interval or surgical resection, follow-up screening should include (multiple answers allowed): EUS 79.6% MRI 69.4%, CT 22.4%, abdominal ultrasound 4.1%, ERCP 2.0%
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